Cipla And Lilly Expand Partnership With YurPEAK Distribution Deal

Key Developments  
- Cipla and Eli Lilly have formalized a distribution and promotion agreement for YurPEAK, expanding their strategic partnership in India  
- YurPEAK is part of Lilly’s diabetes care portfolio and is expected to support better glycemic control in patients with Type 2 diabetes  
- Cipla will handle marketing, distribution, and promotional activities for YurPEAK, leveraging its extensive reach across hospitals and pharmacies  
- The agreement reflects both companies’ commitment to improving access to advanced therapies for chronic diseases in India  
- This follows earlier collaborations between Cipla and Lilly for insulin-based products like Humalog and Trulicity  
- The partnership aligns with Cipla’s broader strategy to strengthen its chronic care offerings and Lilly’s goal to deepen its footprint in emerging markets  

The deal is expected to accelerate the availability of innovative diabetes solutions and reinforce Cipla’s leadership in chronic disease management.

Sources: Cipla official press release, Eli Lilly India corporate communications, Moneycontrol, The Hindu BusinessLine